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Abstract
 
The great majority of patients that are intolerant of wheat gluten protein due to celiac disease
 
(CD) are human histocompatibility leukocyte antigen (HLA)-DQ2
 
1
 
, and the remaining few
normally express HLA-DQ8. These two class II molecules are chiefly responsible for the pre-
sentation of gluten peptides to the gluten-specific T cells that are found only in the gut of CD
patients but not of controls. Interestingly, tissue transglutaminase (tTG)-mediated deamidation
of gliadin plays an important role in recognition of this food antigen by intestinal T cells. Here
 
we have used recombinant antigens to demonstrate that the intestinal T cell response to 
 
a
 
-gli-
adin in adult CD is focused on two immunodominant, DQ2-restricted peptides that overlap by
a seven-residue fragment of gliadin. We show that tTG converts a glutamine residue within
this fragment into glutamic acid and that this process is critical for T cell recognition. Gluten-
specific T cell lines from 16 different adult patients all responded to one or both of these deam-
idated peptides, indicating that these epitopes are highly relevant to disease pathology. Binding
studies showed that the deamidated peptides displayed an increased affinity for DQ2, a mole-
cule known to preferentially bind peptides containing negatively charged residues. Interest-
ingly, the modified glutamine is accommodated in different pockets of DQ2 for the different
epitopes. These results suggest modifications of anchor residues that lead to an improved affin-
ity for major histocompatibility complex (MHC), and altered conformation of the peptide–
MHC complex may be a critical factor leading to T cell responses to gliadin and the oral intol-
erance of gluten found in CD.
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Introduction
 
Celiac disease (CD)
 
1
 
 is the most common food-sensitive
enteropathy in humans, with an incidence as high as 1/300
in some European countries. It is a chronic inflammatory
disease that has become a valuable model for the study of
HLA-associated diseases because there is a well defined
HLA class II association (1, 2), it is relatively easy to obtain
biopsies from the disease-affected organ, and the antigen
that precipitates disease is known.
The observation that CD is strongly associated with
 
DQ2 encoded by DQA1
 
*
 
0501/DQB1
 
*
 
02 or DQ8 en-
coded by DQA1
 
*
 
03/DQB1
 
*
 
0302 implies that CD4
 
1
 
 T
cells play a central role in disease pathogenesis. Indeed, glu-
ten-specific, CD4
 
1
 
 intestinal T cells can be isolated from
intestinal biopsies of CD patients but not of controls (3, 4).
These CD4
 
1
 
 cells are TCR-
 
a
 
/
 
b
 
1
 
 and typically of the Th1
phenotype secreting large amounts of IFN-
 
g
 
 (5), a cyto-
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Abbreviations used in this paper:
 
 CD, celiac disease; TCC, T cell clone;
TCL, T cell line; tTG, tissue transglutaminase. 
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kine that has been linked to mucosal damage (6). A striking
and significant aspect of the intestinal T cell recognition of
gluten is that it is predominantly restricted by DQ2 or
DQ8 (3, 7), the very same molecules that immunogenetic
studies have identified as conferring susceptibility to CD.
These two molecules share an unusual preference for bind-
ing peptides containing negatively charged residues at rela-
tive positions P4, P6, or P7 for DQ2 (8–10) and P1, P4, or
P9 for DQ8 (11, 12). Initially, it was difficult to reconcile
the DQ2 peptide binding motif with the DQ2-restricted
presentation of multiple gluten peptides, as gluten has re-
markably few negatively charged residues. This puzzle was
explained by the recent demonstration that gluten, which
has an exceptionally high glutamine content, becomes a far
better T cell antigen once it been deamidated (13). Fur-
thermore, this conversion of glutamine to glutamic acid has
been shown to be mediated in an ordered and specific fash-
ion by tissue transglutaminase (tTG; references 14 and 15),
an enzyme that is also the major target of autoantibodies in
CD (16).
To understand the disease pathology in CD and to ex-
plain its association with DQ2, it will be critical to dissect
the relationship between the function and specificity of
tTG, the processing of gliadin, and the binding of gliadin
peptides to DQ2. A first step in this process will be to iden-
tify the gliadin epitopes recognized by CD patients and to
assess their relative immunological importance. A compari-
son of multiple gliadin epitopes may identify common mo-
tifs that are targeted by tTG or that influence MHC class II
binding and will allow for the significance of deamidation
on T cell recognition to be more fully examined at a mo-
lecular level. However, the identification of gliadin T cell
epitopes has been hampered by the heterogeneous nature
of this antigen. Wheat gluten can be roughly separated into
the glutenins and the gliadins according to alcohol solubil-
ity. The majority of the gluten-specific T cells appear to
recognize the alcohol-soluble gliadin fraction (3, 13, 17).
The gliadins can be further separated according to primary
sequence into the 
 
a
 
-, 
 
g
 
-, and 
 
v
 
-gliadins, with numerous
variants present within each group (18). No DQ2-restricted
intestinal T cell 
 
a
 
-gliadin epitope has yet been described;
a single 
 
g
 
-gliadin–derived peptide has been identified, but
this is recognized by intestinal T cells from a minority of
patients and does not appear to be a dominant epitope (13).
To circumvent the inherent problems of using natural glia-
dins as antigens (19), we have cloned, sequenced, and ex-
pressed a panel of recombinant 
 
a
 
-gliadins from a commer-
cial Nordic wheat cultivar (20). This study exploits these
antigens to characterize the response to the 
 
a
 
-gliadins us-
ing a panel of T cell clones (TCCs) and T cell lines (TCLs)
established from intestinal biopsies taken from DQ2
 
1 
 
CD
patients.
 
Materials and Methods
 
Production of 
 
a
 
-Gliadin Recombinants.
 
The production of 
 
a
 
-gli-
adins has been described in detail elsewhere (20). In brief, mature
 
a
 
-gliadin genes were cloned from both cDNA and genomic
 
DNA from the commercial Nordic wheat strain, Mjolner. 11
full-length clones were identified and expressed in 
 
Escherichia coli
 
using the pET 17xb expression system (Novagen, Inc.). Gliadin
was extracted from the 
 
E
 
.
 
 coli
 
 by lysing in 70% ethanol at 60
 
8
 
C.
Bacterial cell debris was then removed by centrifugation, and gli-
adin was precipitated by addition of NaCl to 1 M. Coomassie
staining of these preparations run on SDS-PAGE revealed single
dominant bands of appropriate weight with only minor contami-
nation. For purification of T cell–active fragments, 10 mg of 
 
a
 
-9
dissolved in 8 M urea/0.4 M NH
 
4
 
HCO
 
3
 
, pH 8.0, was reduced
and alkylated (21), dialysed against 0.1 M NH
 
4
 
HCO
 
3
 
/0.1 mM
CaCl
 
2
 
,
 
 
 
and digested with chymotrypsin (1:100 wt/wt). This was
passed over a Superdex Peptide HR 10/30 column (Amersham
Pharmacia Biotech) in a 0.1 M NH
 
4
 
HCO
 
3 
 
buffer, vacuum dried,
and resuspended in 100 
 
m
 
l of 5 mM Tris/0.8 mM CaCl
 
2 
 
with
100 
 
m
 
g/ml of guinea pig tTG (Sigma Chemical Co.). T cell–
reactive fragments were further separated by anion exchange chro-
matography (Mono-Q PC 1.6/5) equilibrated with 5 mM Tris/
HCL buffer, pH 5.5, and developed with a gradient ending at 50
mM NaCl, followed by reverse-phase HPLC (
 
m
 
RPC C2/C18;
Pharmacia) using a gradient running from 100% buffer A (0.1%
TFA in H
 
2
 
O) to 100% buffer B (80% acetonitrile, 19.9% H
 
2
 
O,
0.1% TFA). Mono-Q and reverse-phase HPLC were run on a
SMART system (Pharmacia).
 
Preparation of Antigens.
 
Digestion of crude gliadin with either
pepsin and trypsin (3) or chymotrypsin (14) was done as de-
scribed. The overlapping A-gliadin peptides were identical to
those previously described (22). All remaining peptides were sup-
plied by Research Genetics and were 
 
.
 
80% pure. Acid/heat
treatment was achieved by dissolving peptides in 100 
 
m
 
l of 0.01 M
CH
 
3
 
COOH, pH 1.8, and heating at 96
 
8
 
C until dry. Human
tTG was expressed as a GST fusion protein in 
 
E.
 
 
 
coli
 
 using the
vector construct and protocols described by Lai et al.
 
 
 
(23).
 
 
 
Treat-
ment with human and guinea pig tTG (Sigma Chemical Co.) was
performed at 37
 
8
 
C in PBS plus 0.8 mM CaCl
 
2
 
 using 50–200
 
m
 
g/ml of tTG for 3 h.
 
Gliadin-specific T Cells.
 
T cells were grown and assayed in
RPMI 1640 media (GIBCO BRL) supplemented with 15% inac-
tivated pooled human serum, penicillin/streptomycin, and 0.01 M
2-ME. Biopsies from the Norwegian patients were challenged
overnight in an organ culture chamber by immersion in gliadin
antigen (3, 14). Biopsies from patients CD377, CD414, CD416,
CD419, CD420, CD421, and CD424 were challenged with chy-
motrypsin-digested gliadin. The remaining patients were chal-
lenged with a pepsin and trypsin digest of gliadin. Four different
batches of gliadin were used: gliadin extracted from commercial
gluten from Fluka AG or Sigma Chemical Co., extracted from
the Norwegian commercial flour Regal (Regal Mølle a.s.), or ex-
tracted from flour prepared from the wheat strain Kadett. Biop-
sies from patient CD427 were taken from an untreated patient at
the time of diagnosis. The remaining Norwegian patients were
on gluten-free diets. Biopsies were treated with collagenase A to
produce a single-cell suspension that was added to 96 U-bot-
tomed plates containing equal numbers of irradiated autologous
PBMCs together with 10 U/ml IL-2 and cultured in 5% CO
 
2
 
 at
37
 
8
 
C. These TCLs were restimulated weekly with PHA and IL-2
(3) and typically tested between weeks 2 and 4.
The Dutch TCLs established from pediatric biopsies were es-
tablished using a different restimulation strategy. In brief, biopsies
were incubated twice in 1 mM dithiothreitol at room tempera-
ture for 10 min, washed, and then incubated at 37
 
8
 
C for at least
1 h in 0.75 mM EDTA while being gently agitated. The biopsy
cells were then washed twice before being placed in one well of a 
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96-well culture plate containing RPMI media supplemented
with 10% human serum, gentamicin, and 20 
 
m
 
g/ml of pepsin and
trypsin–digested gliadin (Fluka AG). These cultures were restim-
ulated with irradiated autologous PBMCs that had been pre-
pulsed with 20 
 
m
 
g/ml of pepsin and trypsin–digested gliadin ev-
ery 7–10 d and typically tested after 3–4 wk. For one of the
TCLs, the antigen was treated with tTG before restimulation.
The TCL derived from a Dutch adult patient was generated using
the protocol described in reference 17.
 
Proliferation Assays.
 
Duplicate or triplicate wells containing
irradiated APCs (5 
 
3 
 
10
 
4
 
 cells per well; DR3
 
1
 
DQ2
 
1
 
 B lympho-
blastoid cell lines) were prepulsed overnight with peptide or di-
gested gliadin in a volume of 100 
 
m
 
l. 5 
 
3 
 
10
 
4
 
 T cells per well in
50 
 
m
 
l were added the following day, and [
 
3
 
H]thymidine was
added 2 d later. Plates were harvested after a further 12–16-h in-
cubation, and [
 
3
 
H]thymidine incorporation was counted on a Be-
taplate Counter (Wallac Turku). All assays were performed two
or more times with similar results each time.
 
HLA-DQ2 Peptide Binding Assay.
 
An 
 
125
 
I-labeled indicator
peptide (KPLLIIAEDVEGEY) was used in a competitive binding
assay using affinity-purified HLA-DQ2(
 
a
 
1
 
*
 
0501,
 
b
 
*
 
0201) mole-
cules as described (8). Binding affinity is presented in the figures
as the concentration of unlabeled gliadin peptide required to in-
hibit indicator peptide binding by 50% (IC
 
50
 
).
 
Mass Spectrometry.
 
Matrix-assisted laser desorption/ioniza-
tion (MALDI) spectra were acquired on a Reflex II time-of-
flight mass spectrometer (Bruker Daltonik). For tandem mass
spectrometry (MS/MS) experiments (24), a nanoelectrospray ion
trap (Esquire, Bruker Daltonik) or a nanoelectrospray Q-TOF
(Micromass) was used.
 
Results
 
Gluten-specific Intestinal TCCs Recognize a Limited Number
of Recombinant 
 
a
 
-Gliadins.
 
To investigate the nature and
number of DQ2-restricted T cell epitopes present within
the 
 
a
 
-gliadin family, we tested a panel of 11 different 
 
a
 
-gli-
adin recombinants for their ability to stimulate 7 intestinal
TCCs derived from 4 CD patients (Table I). The recombi-
nant antigens were digested with chymotrypsin to solubi-
lize them and then pretreated with tTG to deamidate
them before addition to the proliferation assays. The clones
from patients CD412, CD370, and CD387 were chosen
because they all recognized a purified natural 
 
a
 
-gliadin but
exhibited different response patterns toward two purified
natural 
 
g
 
-gliadins. Clones CD380 E3 and CD380 E37
were randomly chosen. Testing of the 
 
a
 
-recombinants
without prior treatment with tTG failed to stimulate any of
the clones (data not shown). However, after tTG treat-
ment, five of the recombinant 
 
a
 
-gliadins were recognized
by two or more of the TCCs. The recombinant 
 
a
 
-2 stimu-
lated all of the TCCs efficiently, whereas strong prolifera-
tive responses to a-8, a-9, a-10, and a-11 were detected
for only two clones from patient CD387. The remaining
six gliadins failed to stimulate any of the recombinant glia-
dins tested, suggesting that this panel of TCCs recognizes a
limited number of epitopes.
Identification of a DQ2-restricted T Cell Epitope in Recombi-
nant Gliadin a-9. A peptide fragment containing the T
cell epitope present in the a-9 recombinant was isolated by
a series of biochemical purification steps using T cell reac-
tivity with CD387 E34 to identify the positive fractions
(Fig. 1). The recombinant was digested with chymotrypsin
and then separated using size exclusion chromatography.
The resulting fractions were treated with recombinant hu-
man tTG and tested for recognition by the TCC CD387
E34. The fraction containing the smallest peptides that still
efficiently stimulated the TCC (fraction 29) was then sepa-
rated using ion exchange chromatography (Mono-Q; Fig.
1 A). Two T cell–reactive Mono-Q fractions were then
subjected to reverse-phase HPLC separation. Both pro-
duced a single fraction capable of stimulating TCC CD387
E34 (Fig. 1 B). Analysis of these fractions by MALDI-TOF
mass spectrometry yielded a single signal of 1,438.6 daltons.
Analysis of the sequence for the a-9 recombinant identified
no obvious chymotrypsin fragments of this mass. However,
nine peptides were identified that were of an appropriate
mass when deamidation of glutamine to glutamic acid (or
pyroglutamic acid if glutamines were present at the NH2
terminus) were taken into consideration. A comparison be-
tween the T cell reactivity of the recombinants and the
presence or absence of each of these candidate peptides ex-
cluded eight of the nine from being the probable peptide
recognized by CD387 E34 (Table II). However, one pep-
Table I. Recognition of a Panel of tTG-treated Recombinant a-Gliadin Antigens by Seven TCCs
TCC + a-1 a-2 a-3 a-4 a-5 a-6 a-7 a-8 a-9 a-10 a-11
412 R3 13.8 0.9 32.3 1.0 1.0 1.2 1.1 1.5 1.4 1.3 2.3 2.4
412 R5.32 15.7 1.2 19.0 0.9 1.1 1.2 1.2 1.1 1.2 0.9 1.6 0.9
370 R2.3 17.7 1.1 5.0 0.9 1.1 0.3 1.2 1.0 1.4 1.3 4.3 4.6
387 E9 52.6 1.0 25.0 ND 0.8 ND 1.2 1.2 6.1 25.3 23.7 19.4
387 E34 25.1 0.9 25.1 ND 1.0 ND 1.3 1.1 5.0 15.2 15.3 16.2
380 E3 2.4 1.0 2.2 ND 0.9 ND 1.3 1.1 1.1 1.0 0.6 1.0
389 E37 6.5 1.1 3.7 1.1 1.2 1.6 1.4 1.0 2.8 2.1 ND ND
Seven TCCs isolated from four CD patients were tested for recognition of chymotrypsin-digested, tTG-treated gliadins. Gliadin from the wheat
variety Kadett was used as a positive control (1). Results are given as the stimulation index that was calculated by dividing the response to antigen
by the response to PBS control. Similar results were also obtained when pepsin-digested recombinant gliadins treated with acid/heat were used.606 Recognition of a-Gliadins by Gut-derived T Cells in Celiac Disease
tide spanning residues 57–68 of the a-9 recombinant con-
tains a sequence that is present in the a-2, a-8, a-9, a-10,
and  a-11 recombinants, all of which are recognized by
CD387 E34. The remaining a-recombinants all contain se-
quence variation within this peptide and are not recognized
by this TCC. The identity of the epitope in a-9 was con-
firmed by testing a synthetic peptide corresponding to the
a-9(57–68) sequence for its ability to stimulate TCC
CD387 E34. This peptide was inactive in its native form
but potently stimulated the clone after treatment with tTG
(Fig. 2 A). This peptide also stimulated clones CD387 E9,
CD380 E3, and CD380 E37 in a similar fashion (data not
shown). Clones CD380 E3 and CD380 E37 were the least
reactive of the seven clones, which may explain why no
proliferation was detected when they were tested with re-
combinants containing this peptide. Experiments using al-
logeneic APCs and blocking antibodies have confirmed
that these clones recognize this peptide in the context of
DQ2 (data not shown).
Identification of a DQ2-restricted T Cell Epitope in Recombi-
nant Gliadin a-2. The TCC from patients CD370 and
CD412 recognized the a-2 recombinant alone and so pre-
sumably recognizes a peptide that is absent in the other re-
combinants. Although several such regions are present in
the a-2 recombinant, one region (amino acids 62–81) is
noteworthy because it shares considerable homology with
the a-9(57–68) epitope. This is due to the presence of a
triple repeat of a 7-mer motif in the a-2 gliadin, a motif
that is only present once in the a-9 recombinant. A 12-mer
peptide, a-2(62–75), corresponding to two of these repeats
was tested for its ability to stimulate the clone CD412
R5.32. This peptide efficiently stimulated this clone after
treatment with tTG but not in its native form (Fig. 2 B).
Clones CD412 R3 and CD370 R2.3 gave similar results
when tested with this peptide. Proliferation assays using al-
logeneic APCs as well as blocking antibodies confirmed
that this peptide is presented for T cell recognition by DQ2
(data not shown).
Deamidation of a Single Glutamic Acid Residue Is Critical for
T Cell Recognition of the a-9(57–68) and a-2(62–75) Pep-
tides. The  a-2(62–75) and a-9(57–68) peptides were
only recognized by the TCC after deamidation with tTG
or in conditions known to promote nonenzymatic deami-
dation (i.e., heating in an acidic environment). To identify
the number and position of glutamine residues targeted by
tTG, we separated the a-2(62–75) and a-9(57–68) pep-
tides by Mono-Q chromatography after first treating them
with recombinant human tTG. Analysis of the a-9(57–68)
peptide indicated that a single new peptide peak had been
created by treatment with tTG. Mono-Q fractions con-
taining this peak efficiently stimulated TCC CD387 E34
(Fig. 1 C). This fraction was methyl-esterified to label the
deamidation site with a methyl-ester group, and this posi-
Figure 1. Biochemical purification of a peptide fragment from a-9 re-
combinant stimulatory for TCC CD387 E34. A T cell–reactive superdex
fraction of the tTG-treated a-9 recombinant chymotrypsin digest was
separated by ion exchange chromatography (A). The absorbency at 216
nm is overlaid on a histogram depicting the proliferative response of
TCC CD387 E34 to the resulting fractions. Fractions 18 and 19 were
further separated by reverse-phase HPLC, each producing a small T cell–
reactive peak in fraction 14 (fraction 19 shown in B). tTG treatment of
synthetic peptide a-9(57–68) and separation by Mono-Q generates a new
peak at fractions 17 and 18 that is recognized by TCC CD387 E34 (C).
Table II. Comparison of T Cell Recognition and Sequence for 
a-Gliadin Recombinants
Recognition of the a-gliadin recombinants is compared with their
sequences. Negative responses (2) all had a stimulation index of 1.6 or
less, whereas positive responses (1) were greater than or equal to 5. The
shaded region in the a-9 recombinant marks a peptide with a suitable
mass to that obtained by MS analysis and is present in all gliadins that
stimulated the clone. The shaded region in a-2 marks a related but
unique sequence present only in this recombinant.607 Arentz-Hansen et al.
tion was identified as residue 65 by MS/MS analysis (pep-
tide a-9[57–68]E65; reference 25). Two peaks were cre-
ated by the tTG treatment of the a-2(62–75) peptide, both
of which were stimulatory for the TCC CD412 R5.32
(data not shown). Mass spectrometry analysis revealed that
the least acidic of these two peaks contained a peptide in
which the glutamine at position 65 had been deamidated
(peptide a-2[62–75]E65). The more acidic peak contained
a peptide with glutamines deamidated at residues 65 and
72. Confirmation that the deamidation of glutamine at po-
sition 65 was critical for T cell recognition of both pep-
tides was given by testing synthetic peptides with gluta-
mines substituted with glutamic acid. Peptides containing
glutamic acid at position 65 stimulated TCCs CD412 R5.32
and CD387 E34 extremely efficiently; the remaining pep-
tides could, at best, only stimulate the TCCs very weakly
when high concentrations of peptide were used (Fig. 3).
Testing for recognition of both the a-9(57–68)E65 and
a-2(62–75)E65 peptides demonstrated that these epitopes
were not cross-reactive for this panel of TCCs (data not
shown).
Binding of the a-9(57–68) and a-2(62–75) Peptides to
DQ2. The minimal core binding region and the binding
frame for a-2(62–75) and a-9(57–68) peptides was charac-
terized by measuring the affinity of a set of truncated and/
or glutamic acid– and lysine-substituted peptides for DQ2
in a cell free binding assay (Fig. 4). The affinity for DQ2 of
the a-2(62–75) and a-9(57–68) peptides increased dramat-
ically when the peptides were first heated in an acidic envi-
ronment or when a glutamic acid was substituted at the
position identified as important for T cell recognition. In-
terestingly, substitution of glutamic acid residues at some
other positions resulted in a comparable increase in affinity
of the peptide for DQ2 but did not lead to T cell recogni-
tion (Fig. 4 and data not shown). This implies that recogni-
tion of these deamidated peptides is a combined result of an
increase in peptide binding and a change in conformation
of the peptide–MHC complex.
Removal of the COOH-terminal tyrosine residue from
the a-9(57–68) peptide effectively abolished DQ2 binding
(Fig. 4 A) and T cell recognition (data not shown), strongly
suggesting that this residue acts as an anchor in the P9
pocket. This would position residues 57, 58, and 59 at P3,
P2, and P1, respectively. Successive truncation of the peptide
at these positions leads to a progressive loss of affinity for
DQ2 and T cell recognition (data not shown), most likely
due to a loss in hydrogen bonding between the main chain
residues in the peptide and DQ2. A similar progressive loss
of affinity for DQ2 was seen for the a-2(62–75) peptide
truncated at the COOH terminus. However, the removal of
the glutamine at position 70 reduced the binding to unde-
tectable levels, indicating that this residue act as the P9 an-
chor. T cell recognition of these truncated peptides gave re-
sults comparable to the binding data (data not shown).
Figure 2. Recognition of peptides a-9(57–68) and a-2(62–75) by two
TCCs. Peptides a-9(57–68) (A) and a-2(62–75) (B) were tested in their
native state (r) or after treatment with human tTG (j) or acid/heat (a/h;
m) for their ability to induce proliferation in (A) TCC CD387 E34 and
(B) TCC CD412 R5.32. Responses are given in cpm.
Figure 3. Testing of synthetic glutamine to glutamic acid–substituted
peptides for their ability to stimulate TCCs. TCC CD387 E34 (A) and
TCC CD412 R5.32 (B) were tested for recognition of a set of singly sub-
stituted peptides that had the glutamine residues substituted for glutamic
acid residues.608 Recognition of a-Gliadins by Gut-derived T Cells in Celiac Disease
Previous peptide binding studies have clearly demon-
strated that positively charged residues inhibit peptide
binding to DQ2 at relative positions P4, P6, or P7 but are
well tolerated at P5, a position thought to point toward the
T cell receptor (10). We therefore reasoned that the as-
sumed binding frames for the a-2(62–75)E65 and a-9(57–
68)E65 peptides could be confirmed by measuring DQ2
binding using lysine-substituted peptides at the tentative
P4, P5, and P6 residues (Fig. 4 A). The binding to DQ2 of
the a-9(57–68)E65 peptide dropped to below the accurate
detection level for our assay when single lysine residues
were substituted at positions 63 and 65. In contrast, the
a-9(57–68)E65 peptide with a lysine substituted at position
64 showed only a marginal decrease in binding to DQ2.
Similarly, the DQ2 binding of the a-2(62–75) peptide was
inhibited by lysine substitutions at positions 65 and 67 but
unaffected by lysine at position 66 (Fig. 4 B). The doubly
deamidated peptide was chosen for these experiments be-
cause initial T cell experiments indicated that this tTG-cre-
ated variant gave greater responses. Together, these data
clearly show that despite overlapping by some seven resi-
dues, the a-2(62–75) and a-9(57–68) peptides bind in a
different frame to DQ2, with the glutamic acid residue
binding in the P4 and P6 pockets, respectively.
The a-9(57–68) and a-2(62–75) Peptides Are Commonly
Recognized Gliadin Epitopes. The peptide specificity of
seven clones derived from four CD patients could be ac-
counted for by the a-2(62–75)E65 and a-9(57–68)E65
peptides alone, suggesting that these may be dominant glia-
din epitopes that are frequently recognized by CD patients.
To further assess their importance, we screened a panel of
gluten-specific, polyclonal intestinal TCLs established from
17 CD patients for recognition of the a-2(62–75)E65 and
a-9(57–68)E65 peptides (Fig. 5). TCLs from 12 of these
patients made clear responses to the a-9(57–68)E65 pep-
tide (with a stimulation index $2), whereas 11 made re-
Figure 4. Analysis of peptides a-9(57–68)
and a-2(62–75) binding to DQ2. Acid/heat
(a/h)-treated, glutamic acid–substituted, and
truncated peptide variants of the (A) a-9(57–
68) and (B) a-2(62–75) peptides were assessed
for binding to DQ2 using a cell free competi-
tive binding assay. The presumed binding
frame for the two peptides is marked below
the sequence. Broken bars indicate that pep-
tide binds too poorly to DQ2 to be measured
accurately in this assay.609 Arentz-Hansen et al.
Figure 5. Recognition of peptides a-9(57–68)E65 and a-2(62–75)E65
by polyclonal TCLs. 17 TCLs were tested for recognition of the synthetic
a-9(57–68)E65 and a-2(62–75)E65 peptides at 5 mM. The y-axis crosses
the x-axis at a stimulation index of 1, i.e., where no effect on T cell pro-
liferation is observed.
sponses to the a-2(62–75)E65 peptide. These responses
were greater than or comparable with the responses to the
pepsin and trypsin–digested gliadin at 1 mg/ml or tTG-
treated chymotrypsin gliadin at 500 mg/ml (data not
shown). A gliadin-reactive TCL from a DQ81DQ22 Nor-
wegian patient failed to respond to either peptide. When
TCLs and TCCs were taken together, all 19 of the DQ21
Norwegian patients were shown to have T cell responses to
one or both of the a-2(62–75)E65 and a-9(57–68)E65
peptides (Table I and Fig. 5). Recognition of tTG-treated
a-2(62–75) and a-9(57–68) peptides was also analyzed us-
ing intestinal TCLs isolated from five Dutch children and a
single Dutch adult (data not shown). Surprisingly, TCLs
from only two patients responded to the peptides; the TCL
from one child that was restimulated with tTG-treated,
pepsin and trypsin–digested gliadin responded to both of
the tTG-treated peptides, whereas the adult-derived TCL
responded to the a-2(62–75) peptide after tTG treatment.
There were no responses detected in the Dutch TCLs to
the non–tTG-treated a-2(62–75) and a-9(57–68) peptides.
The a-9(57–68) and a-2(62–75) Peptides Are the Immu-
nodominant Intestinal T Cell Epitopes in a-Gliadin. The
a-9(57–68) and a-2(62–75) peptides are clearly major
epitopes within a-gliadin. To investigate if other a-gliadin
epitopes are present within the a-recombinants, we tested
eight polyclonal gluten-specific TCLs isolated from DQ21
adult CD patients for recognition of a panel of the a-glia-
din recombinants. The recombinants were digested with
either chymotrypsin or pepsin before treatment with tTG
and addition to the proliferation assay. As expected, all of
the TCLs recognized one or both of the a-9(57–68)E65
and a-2(62–75)E65 peptides and the a-2 recombinant that
contains them (Fig. 6). In contrast, recombinants that dis-
played sequence variation within both of these epitopes
failed to stimulate any of the TCLs tested. Furthermore,
TCLs from six patients failed to recognize any of a series of
native and tTG-treated overlapping peptides corresponding
to residues 1–58 of A-gliadin (data not shown). Together,
these data suggest that the a-9(57–68) and a-2(62–75)
peptides are the only common a-gliadin epitopes recog-
nized by T cells from the adult Norwegian CD population.
Discussion
A molecular explanation for disease pathology and HLA
association in CD has been difficult to address due to the
lack of defined gliadin T cell epitopes. We therefore tested
a panel of a-gliadin–recombinant antigens to characterize
the T cell response to a-gliadin using gluten-specific TCCs
and lines grown from intestinal biopsies of CD patients.
Two distinct but overlapping epitopes have been identified
that share a common seven–amino acid motif. Deamida-
tion of the same glutamine residue situated within this
7-mer motif, a modification specifically performed by hu-
Figure 6. Recognition of a-gliadin re-
combinants by a panel of polyclonal TCLs.
Stimulation of polyclonal TCLs by a-9
(57–68) and a-2(62–75) peptides or tTG-
treated a-recombinants that have been di-
gested with pepsin or chymotrypsin. Pep-
tides were tested at 5 mM. Recombinant
a-gliadins and gliadin from the wheat vari-
ety Kadett were tested at 50 mg/ml. Data is
shown for five representative TCLs out of
eight that were tested.610 Recognition of a-Gliadins by Gut-derived T Cells in Celiac Disease
man tTG, is critical for the T cell recognition of these pep-
tides. The two a-9(57–68)E65 and a-2(62–75)E65 pep-
tides appear to be the dominant epitopes within the a-gliadin
family, and between them they are recognized by most if
not all adult CD patients. It is intriguing that the a-gliadin
T cell response is focused on a single repetitive fragment of
gliadin and that this is also targeted by tTG. It is possible
that the specificity of tTG plays a more central role in the
selection of gliadin T cell epitopes in the gut than has been
appreciated.
In vivo and in vitro studies have identified a-gliadins as a
major source of toxicity for CD patients (26–29). Our
study confirms that these proteins are also a major focus of
the intestinal T cell response to gluten. Notably, they do
not correspond with the A-gliadin peptides previously
identified as active in CD (22, 30–32). The failure of the
polyclonal intestinal TCLs to recognize either the native
or tTG-treated a-gliadins lacking the a-9(57–68) and a-2
(62–75) sequence or native or tTG-treated A-gliadin pep-
tides indicates that these patients do not make significant
responses toward other a-gliadin peptides.
The disparity in recognition for the a-9(57–68) and
a-2(62–75) peptides between the TCLs isolated in Norway
and The Netherlands may well relate to differences in the
restimulation strategy and antigen used for generating
them. The Norwegian biopsies were challenged by immer-
sion overnight in enzyme-digested gliadin in an organ cul-
ture system (3). We have recently found that under these
conditions, the gliadin is deamidated in situ by endogenous
tTG (Molberg, Ø., S.N. McAdam, K.E.A. Lundin, C.
Kristiansen, H. Arentz-Hansen, K. Kett, and L.M. Sollid,
manuscript in preparation). In contrast, the Dutch pediatric
biopsies were first disrupted with dithiothreitol and EDTA
and then cultured in a 96-well plate containing a relatively
low concentration of pepsin and trypsin–digested gliadin.
These cultures were then restimulated two to three times
with irradiated autologous PBMCs that had been prepulsed
with pepsin and trypsin–digested gliadin. Notably, this an-
tigen failed to stimulate the Dutch peptide-specific TCLs
unless it had been pre-treated with tTG, indicating that it
was only minimally deamidated. Furthermore, the single
pediatric line that responded to the peptides was the only
Dutch TCL that had been restimulated with tTG-treated,
pepsin and trypsin–digested gliadin. Thus, the protocol
used to generate the TCLs from the pediatric biopsies
should not efficiently expand T cells specific for the a-9
(57–68)E65 and a-2(62–75)E65 peptides. However, it is
possible that there are also differences in gliadin specificity
in the T cells with adult and pediatric patients. Ongoing
work will investigate this possibility.
It is currently unclear how oral tolerance is established in
humans. It is conceivable, however, that tTG-mediated
deamidation plays a central role in the loss of oral tolerance
to gliadin in CD. Deamidation is critical and necessary for
the intestinal T cell recognition of the a-9(57–68) and
a-2(62–75) peptides and of a DQ2-restricted g-gliadin
epitope (13). Enzymatic deamidation of these three pep-
tides converts them from epitopes that bind weakly but sig-
nificantly to DQ2 to epitopes with a reasonable but by no
means exceptional affinity. It is notable that the g-gliadin
epitope shares no unusual sequence motif with the a-9(57–
68) and a-2(62–75) peptides and that the modified glu-
tamine residue for each of these epitopes occupies a dif-
ferent pocket within DQ2 (33). This suggests that rather
than recognition of a single “pathogenic motif,” it is the al-
tered affinity of deamidated gliadin peptides for DQ2 that
may be a critical factor involved in loss of tolerance. Con-
current with the increase in affinity for DQ2 induced by
deamidation is a change in conformation of the gliadin–
DQ2 complex. This is indicated by the failure of the TCCs
to recognize the unmodified peptides or peptides contain-
ing glutamic acid residues at anchor residues not targeted
by tTG but with affinity for DQ2 similar to that of the E65
peptides. Interestingly, the simple modification of gluta-
mine residues that act as major TCR contact residues does
not appear to be sufficient to break tolerance, as none of
the modified glutamines are found at this position. This in-
dicates that changing the DQ2/peptide conformation alone
does not lead to a loss of tolerance and emphasizes the re-
quirement for a change in affinity of the gliadin peptide
with the DQ2 molecule.
A major role of tTG in vivo is the extracellular cross-
linking of glutamine residues with primary amines via
isopeptide bonds (34). Deamidation of glutamines is fa-
vored over their incorporation into isopeptide bonds when
lysine/polyamine concentrations are low. The unusual
ability of gliadins to act as excellent amine acceptor sub-
strates for tTG (34, 35) could lead to a local depletion in
the concentration of lysine/polyamine and create microen-
vironments where deamidation of gliadin is likely. Gliadin
fragments containing two glutamine residues targeted by
tTG may well be deamidated and cross-linked to other
lysine-containing proteins. Conditions may exist in the gut
where T cell epitopes are both created and trapped locally
by tTG, prohibiting their presentation by “tolerogenic”
APCs in the gut. Alternatively, it may prevent these
epitopes from spreading systemically as soluble antigen, a
factor shown to be important in oral tolerance (36). An im-
plication of this would be that administration of soluble
deamidated gliadin peptides to CD patients should induce
tolerance to gliadin. This therapeutic approach becomes
practical with the identification of this immunodominant
fragment and as it becomes apparent that fewer gliadin
epitopes exist as was initially predicted (37).
If the gliadin fragments were cross-linked to tTG itself, a
phenomenon known to occur in vitro, then gliadin-spe-
cific T cells may provide “help” for tTG-specific B cells.
We have proposed that this mechanism may explain the in-
triguing observation that anti-tTG autoantibody produc-
tion is dependent on gliadin exposure (38). It may there-
fore be significant that the motifs targeted by tTG and
shared in the a-9(57–68) and a-2(62–75) epitopes is re-
peated in many a-gliadins.
An unusual feature of the a-9(57–68) and a-2(62–75)
peptides is the presence of multiple proline residues at rela-
tive positions P1, P3, P6, and P8 and P1, P3, P5, and P8,611 Arentz-Hansen et al.
respectively. These residues may serve to protect from pro-
teolytic cleavage during luminal digestion and/or class II
processing. It is unusual for natural class II ligands to have
more than one proline residue within the core binding re-
gion (39). Moreover, class II peptide binding studies have
rarely shown that proline residues have a positive influence
on binding (40–43). It is tempting to speculate that DQ2
and DQ8 may be unique in their ability to accommodate
peptides with repetitive proline residues and have a strong
preference for binding peptides with negatively charged
residues. Therefore, the basis of the HLA association in CD
may be founded on the unique peptide binding properties
of these two molecules.
Here we have demonstrated that intestinal T cell recog-
nition of an immunodominant fragment of a-gliadin is
dependent on the enzymatic modification of a single
glutamine residue. These findings provide a new molecular
perspective to analyze the mechanisms leading to wheat in-
tolerance in CD that should yield new insights into the
mechanisms of oral tolerance in humans.
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